NCT01089309已完成4 期
Effect of Aldosterone Blockade on Metabolic Parameters and Arterial Compliance
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 51
- 试验地点
- 1
研究概览
简要总结
The present study investigated the long-term (12 months) effect of spironolactone treatment on glucose homeostasis, metabolic parameters and vascular properties.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 45 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients with type 2 diabetes mellitus
排除标准
- •history of unstable angina, myocardial infarction (MI), cerebrovascular accident (CVA)
- •major surgery within the six months preceding entrance to the study
- •unbalanced endocrine disease
- •any disease that might affect absorption of medications
- •plasma creatinine >2.5 mg/dl
- •elevation of liver enzymes to more that twice the upper normal limit
- •plasma potassium levels >5.5 mg/dl
研究组 & 干预措施
Aldosteron blokade, Arterial stiffness, Glucose homeostasis
Experimental
干预措施: Spironolactone (Drug)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
ALdosterone Antagonist Chronic HEModialysis Interventional Survival TrialEnd Stage Renal Failure on DialysisNCT01848639University Hospital, Brest823
Unknown
4 期
Aldosterone in Diabetic NephropathyDiabetic NephropathyNCT00870402Universidad de los Andes, Chile160
已完成
不适用
Optimalization of Nephroprotection Using Agents Inhibiting Renin-Angiotensin-Aldosterone SystemProteinuriaChronic Kidney DiseaseNCT00528385Medical University of Gdansk
已完成
不适用
Mineralocorticoid Receptor and Obesity Induced Cardiovascular ComplicationsObesityInsulin ResistanceNCT01406015Brigham and Women's Hospital38
Unknown
4 期
Cardiovascular Protective Effect of Spironolactone in HemodialysisHemodialysisNCT00277693Universidad de los Andes, Chile